New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
09:05 EDTORCL, ITMN, ACAD, TUMI, GES, MOV, PERY, AZN, YHOO, CSCO, SCHLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Perry Ellis (PERY), up 5.2%... Movado (MOV), up 2.4%... ALSO HIGHER: InterMune (ITMN), up 12.2% after health technology appraisal body in England and Wales recommends use of its Esbriet drug... ACADIA (ACAD), up 7.5% after presenting detailed results from a Phase III study of its treatment for Parkinson's disease psychosis... AstraZeneca (AZN), up 2.8% after saying it plans to restructure its SG&A activities to cut out about 2,300 jobs, announcing partnership agreement with Moderna Therapeutics... Yahoo! (YHOO), up 2% following upgrade at Oppenheimer... DOWN AFTER EARNINGS: Oracle (ORCL), down 7.6%... Guess (GES), down 6%... Tumi (TUMI), down 6%... Scholastic (SCHL), down 11.5%... ALSO LOWER: Cisco (CSCO), down 2.5%, following downgrade at FBR Capital... General Moly (GMO), down 21%, after work suspended on a $665M loan being negotiated for the development of its Mt. Hope Project.
News For ORCL;CSCO;YHOO;AZN;PERY;MOV;GES;TUMI;ACAD;ITMN;SCHL From The Last 14 Days
Check below for free stories on ORCL;CSCO;YHOO;AZN;PERY;MOV;GES;TUMI;ACAD;ITMN;SCHL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
August 21, 2014
09:07 EDTGESOn The Fly: Pre-market Movers
Subscribe for More Information
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
07:34 EDTPERYPerry Ellis narrows FY15 EPS view to 85c-95c from 80c-95c, consensus 91c
Subscribe for More Information
07:32 EDTPERYPerry Ellis reports Q2 adjusted EPS (8c), consensus (12c)
Subscribe for More Information
06:43 EDTGESGuess management turnover concerning, says Piper Jaffray
Piper Jaffray says it remains concerned with the continued pattern of management turnover at Guess after the company disclosed the departure of its Chief Design Officer. Piper believes it will take longer to turn around the Guess brand and keeps a Neutral rating on the stock.
06:40 EDTGESGuess discloses resignation of Chief Design Officer
Subscribe for More Information
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
05:22 EDTITMNInterMune downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded InterMune to Market Perform citing valuation.
August 20, 2014
15:26 EDTPERYNotable companies reporting before tomorrow's open
Subscribe for More Information
12:11 EDTYHOOStocks with call strike movement; UAL YHOO
United Continental (UAL) December 55 call option implied volatility decreased 3% to 42, Yahoo (YHOO) November 45 call option implied volatility increased 2% to 42 according to IVolatility.
11:49 EDTYHOOBofA/Merrill telecom services analysts hold an analyst/industry conference call
Analysts discuss the upcoming IPO of Alibaba, which is expected to launch early September 2014, on an Analyst/Industry conference call to be held on August 21 at 8 am.
08:21 EDTPERYPerry Ellis management to meet with Benchmark
Subscribe for More Information
06:26 EDTCSCOCisco COO says annual layoffs 'wrong way to do it,' Business Insider reports
Subscribe for More Information
05:53 EDTITMNStocks with implied volatility movement; NGD ITMN
Subscribe for More Information
August 19, 2014
11:05 EDTCSCOImperva seen as takeover candidate under new CEO
Subscribe for More Information
10:13 EDTGESOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CNOOC (CEO) downgraded to Hold from Buy at Jefferies... Guess (GES) downgraded to Neutral from Overweight at Piper Jaffray... Ingersoll-Rand (IR) downgraded at RW Baird... Lehigh Gas (LGP) downgraded to Neutral from Buy at Ladenburg... Lexicon (LXRX) downgraded to Hold from Buy at Gabelli... Monster Beverage (MNST) downgraded to Neutral from Buy at SunTrust... Nobel Biocare (NBHGY) downgraded to Hold from Buy at Berenberg... Saint Joe Co. (JOE) downgraded to Market Perform from Outperform at Raymond James... SolarCity (SCTY) downgraded at RW Baird.
08:42 EDTCSCOImperva new CEO has history of selling companies, says Sterne Agee
After Imperva (IMPV) appointed Anthony Bettencourt as its new CEO, Sterne Agee says that he has a history of selling companies. The firm believes that Imperva "would likely be an acquisition candidate" for a number of large tech companies such as Cisco (CSC), Juniper (JNPR), HP (HPQ), IBM (IBM), Check Point (CHKP), or F5 (FFIV). Sterne Agee believes that Imperva could be acquired for as much as $45 per share, and it keeps a Buy rating on the stock.
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
06:12 EDTGESGuess downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Guess to Neutral saying the company's turnaround could take more time to play out.
05:48 EDTYHOOStocks with implied volatility movement; AEO YHOO
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use